Truist Financial Reaffirms "Buy" Rating for Roivant Sciences (NASDAQ:ROIV) : vimarsana.com

Truist Financial reiterated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a research report released on Monday, Benzinga reports. Truist Financial currently has a $23.00 price objective on the stock. A number of other research analysts have also recently issued reports on ROIV. TheStreet raised shares of Roivant Sciences from […]

Related Keywords

United States , America , American , Vivek Ramaswamy , Eric Venker , Nasdaq , Blackrock Inc , Securities Exchange Commission , Citigroup Inc , Roivant Sciences Stock Performance , News Ratings For Roivant Sciences Daily , York Mellon Corp , American International Group Inc , Deutsche Bank Aktiengesellschaft , Wolfe Research , Analyst Recommendations For Roivant Sciences , Vanguard Group Inc , Roivant Sciences Ltd , Roivant Sciences , Institutional Trading Of Roivant Sciences , Truist Financial , Free Report , Bank Aktiengesellschaft , Moderate Buy , Get Free Report , Exchange Commission , New York Mellon Corp , American International Group , Sciences Ltd , Roivant Sciences Daily , Nasdaq Roiv , Roiv , Medical , Reiterated Rating , Truist Financial Co ,